Actual LIBTAYO patient.

What is LIBTAYO?

LIBTAYO is the first medicine approved by the Food and Drug Administration (FDA) to treat CSCC that has spread or cannot be cured by surgery or radiation. LIBTAYO is a type of immunotherapy called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.

LIBTAYO may be right for people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that:

Cutaneous squamous cell carcinoma that has spread

Has spread to other
parts on the body
(metastasized)

OR
Cutaneous squamous cell carcinoma may not be cured by surgery or radiation

Cannot be cured by
surgery or radiation

Conversation with John Strasswimmer, MD, PhD

Play the video below to hear insights from a practicing physician.

Think LIBTAYO could be an option for you? Learn more about how LIBTAYO can help you fight advanced CSCC.

Learn more